Severe primary insulin-like growth factor 1 (IGF-1) deficiency (SPIGFD) results in short stature and increased insulin sensitivity in afflicted patients. We are developing MOD-1302, utilizing a stabilizer-based technology, as an extended release IGF-1 repletion therapy for the treatment of SPIGFD.
SPIGFD occurs in roughly 20% of children with isolated short stature.